Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728972 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
A Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 10
- Study locations
NCT03728972 is a Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants. The trial reports 10 study locations across 4 states.
The verdict
NCT03728972, a Phase 2 study of NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (10)
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Hackensack Meridian Health - Hackensack
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
California
- Stanford University - Stanford
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728972
The ClinicalTrials.gov registry entry for NCT03728972 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03728972 reports 10 study locations spanning 4 distinct geographic areas - top geographies include New Jersey, New York, California.
Frequently Asked Questions
What is clinical trial NCT03728972 about?
NCT03728972 is a clinical study titled "Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type". The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
What is the current status of trial NCT03728972?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-11-09. Estimated completion is 2026-11.
What conditions does trial NCT03728972 study?
This clinical trial studies the following conditions: NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis).
What interventions are being tested in trial NCT03728972?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03728972?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03728972 being conducted?
This trial has 10 study locations across California, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
All registered trials for this condition
NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.